The Anxiety Disorder and Depression Treatment Market will increase from US$ 19.39 billion in 2023 to US$ 32.25 billion by 2032, at a CAGR of 5.82% from 2024-2032. Young adults' increased rates of anxiety and depression are a complicated problem with many underlying reasons, such as excessive social media use, pressure to perform well in school, and financial stress, all of which are contributing to the market's expansion. Young adults, generally characterized as those in the 18-30 age range, are among the age groups most susceptible to the dangers of anxiety and depression.
Clinical disorders known as anxiety disorders occur when a person has prolonged worry, fear, or uneasiness. They affect a person's quality of life, social interactions, and day-to-day functioning. Generalized anxiety disorder, panic disorder, social phobia, and phobic fears are the four primary categories of anxiety disorders. Anxiety disorders can manifest in a variety of ways, including somatic ones that impair social, interpersonal, and occupational functioning. They may also result in avoidance behaviors and long-term stress, both of which may have an impact on one's physical health in the future.
Depression is a serious mental illness that results in enduring melancholy, pessimism, and disinterest in activities. It has a significant impact on all facets of a person's life, including their emotional and physical health as well as their cognitive abilities, and affects millions of people globally. In severe circumstances, depression can also result in suicidal thoughts or actions. It can also raise the chance of developing other health issues.
Depression and anxiety disorders are typically treated with a combination of cognitive behavioural therapy, medication, lifestyle modifications, and other therapies. Non-pharmacological treatments are the mainstay and are frequently customized; these may include family, peer, and complementary therapy.
A MindMed study estimates that 284 million people worldwide suffer from anxiety, yet only 36% of them seek help. This is mostly to blame for the decline in the number of prescriptions written to treat depression and anxiety disorders, which has slowed the market's growth. Antidepressant demand is low because people are generally unaware of the need for treatment and management of mental health issues. To increase market potential, industry participants are nevertheless aggressively releasing new medications.
According to data released by the Anxiety and Depression Association of America in 2022, for example, anxiety disorder affected approximately 31.9% of adolescents between the ages of 13 and 18 in 2021 and 6.8 million people in the United States. Furthermore, according to data released by the Canadian Mental Health Association in July 2021, 5.4% of Canadians suffered from severe depressive disorder, and 4.6% from anxiety disorders. Thus, during the course of the forecast period, the rising frequency of depression and anxiety disorders in North American nations is anticipated to fuel market expansion.
In a similar vein, it is anticipated that the increasing number of product approvals in this area will propel market expansion. For instance, Axsome Therapeutics' Auvelity medication was approved by the US FDA in August 2022 to treat major depressive disorder in adults. It is a medication taken orally that works in a unique way.
Anxiety Disorders and Depression Treatment Market Overview
Millions of individuals worldwide suffer from mental health symptoms each year, and the number of those seeking help is on the rise. Living with a mental health diagnosis affects families, communities, and even economies in addition to the patient.Clinical disorders known as anxiety disorders occur when a person has prolonged worry, fear, or uneasiness. They affect a person's quality of life, social interactions, and day-to-day functioning. Generalized anxiety disorder, panic disorder, social phobia, and phobic fears are the four primary categories of anxiety disorders. Anxiety disorders can manifest in a variety of ways, including somatic ones that impair social, interpersonal, and occupational functioning. They may also result in avoidance behaviors and long-term stress, both of which may have an impact on one's physical health in the future.
Depression is a serious mental illness that results in enduring melancholy, pessimism, and disinterest in activities. It has a significant impact on all facets of a person's life, including their emotional and physical health as well as their cognitive abilities, and affects millions of people globally. In severe circumstances, depression can also result in suicidal thoughts or actions. It can also raise the chance of developing other health issues.
Depression and anxiety disorders are typically treated with a combination of cognitive behavioural therapy, medication, lifestyle modifications, and other therapies. Non-pharmacological treatments are the mainstay and are frequently customized; these may include family, peer, and complementary therapy.
A MindMed study estimates that 284 million people worldwide suffer from anxiety, yet only 36% of them seek help. This is mostly to blame for the decline in the number of prescriptions written to treat depression and anxiety disorders, which has slowed the market's growth. Antidepressant demand is low because people are generally unaware of the need for treatment and management of mental health issues. To increase market potential, industry participants are nevertheless aggressively releasing new medications.
Growth Factors in the anxiety disorders and Depression Treatment Industry
The Economic Cost of Mental Illnesses to Drive Product Demand
Due to the immense financial and emotional strain that mental health diseases place on people, families, and society at large, the prevalence of these disorders is rising quickly in both adults and children worldwide. There will be economic ramifications to this in the future. The WHO estimates that the cost of mental health issues in wealthy nations is between 3% and 4% of GDP (gross national product). Consequently, governments' efforts to lessen the financial burden of these illnesses are likely to increase consumer demand for products that provide prompt treatment of depression and anxiety.Sturdy Medication Pipelines to Support Development Prospects
Globally, there is an acceleration of research and development aimed at providing advanced patient care for mental health diseases. Treatment pipeline candidates for depression and anxiety disorders have increased as a result of creative trials that resulted in combination therapies using either novel or existing medication molecules. For example, Luye Pharma reported in March 2020 that the US Food and Drug Administration (FDA) has accepted its new drug application for the depressive medication LY03005. Strong support for research and development funding from national and international healthcare organizations is also anticipated to create a variety of prospects in the market for the treatment of depression and anxiety disorders. This is expected to support market expansion, along with consumers' growing demand for novel medications that are introduced to the market.North America Anxiety Disorders and Depression Treatment Market Overview:
Over the course of the forecast period, the North American region is anticipated to occupy a significant share of the market. The frequency of anxiety and depressive disorders among North Americans is rising, and the industry is predicted to develop due to factors like these, as well as the presence of major competitors and a robust clinical pipeline.According to data released by the Anxiety and Depression Association of America in 2022, for example, anxiety disorder affected approximately 31.9% of adolescents between the ages of 13 and 18 in 2021 and 6.8 million people in the United States. Furthermore, according to data released by the Canadian Mental Health Association in July 2021, 5.4% of Canadians suffered from severe depressive disorder, and 4.6% from anxiety disorders. Thus, during the course of the forecast period, the rising frequency of depression and anxiety disorders in North American nations is anticipated to fuel market expansion.
In a similar vein, it is anticipated that the increasing number of product approvals in this area will propel market expansion. For instance, Axsome Therapeutics' Auvelity medication was approved by the US FDA in August 2022 to treat major depressive disorder in adults. It is a medication taken orally that works in a unique way.
Anxiety Disorders and Depression Treatment Market Company Overview
Some of the industry leaders seen in the Global Anxiety Disorders and Depression Treatment Market Includes Abbvie, Bristol-Myers Squibb Company, Eli Lily & Co, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Merck & Co Inc., Pfizer Inc., Sanofi-Aventis, and Axsome TherapeuticsAnxiety Disorders and Depression Treatment Company News
- In September 2023, At the International Headache Congress (IHC) 2023 in Seoul, Korea, Lundbeck presented clinical results attesting to the efficacy and tolerability of Lu AG09222 in preventing migraines, a prevalent symptom in a significant number of patients with anxiety disorders. Additional data from a trial demonstrating Lu AG09222's ability to stop PACAP38-induced vasodilation and headaches was also included in the presentations.
- In March 2022, The Phase 2 Proof-of-Concept investigator-initiated trial of HMNC Brain Health's oral prolonged-release formulation of ketamine (KET01) in Treatment-Resistant Depression (TRD) produced encouraging top-line findings.
- In February 2022, The US Food and Drug Administration (FDA) received a supplemental New Drug Application (sNDA) from AbbVie for cariprazine (VRAYLAR), intended for use as an adjuvant treatment for major depressive disorder (MDD) in patients undergoing continuous antidepressant therapy.
Product: Market is divided into 3 viewpoints
- Antidepressant Drugs
- Therapy and Devices
- Others
Indication: Market is divided into 4 viewpoints
- Obsessive-Compulsive Disorder
- Major Depressive Disorder
- Phobia
- Others
Country: Market is divided into 24 Countries
North America
- United States
- Canada
Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Netherlands
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Malaysia
- Indonesia
- Israel
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Rest of World
The key players have been covered from 5 viewpoints:
- Key Person
- Company overview
- Recent Development & Strategies
- Product Portfolio
- Sales Analysis
Company Analysis
- Abbvie
- Bristol-Myers Squibb Company
- Eli Lily & Co
- GlaxoSmithKline
- H. Lundbeck A/S
- Johnson & Johnson
- Merck & Co. Inc
- Pfizer Inc
- Sanofi-Aventis
- Axsome Therapeutics
Table of Contents
1 Introduction2 Research Methodology3 Executive Summary5 Anxiety Disorders and Depression treatment Market
4 Market Dynamics
6 Market Share
7 By Product
8 By Indication
9 By Country
10 Porter’s Five Forces Analysis
11 SWOT Analysis
12 Company Analysis
Companies Mentioned
- Abbvie
- Bristol-Myers Squibb Company
- Eli Lily & Co
- GlaxoSmithKline
- H. Lundbeck A/S
- Johnson & Johnson
- Merck & Co. Inc
- Pfizer Inc
- Sanofi-Aventis
- Axsome Therapeutics
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 180 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 19.39 Billion |
| Forecasted Market Value ( USD | $ 32.25 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
